NCT05559008View on ClinicalTrials.gov

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

September 30, 2022

Primary Completion Date

March 26, 2024

Study Completion Date

January 26, 2026

Conditions
Peripheral T Cell Lymphoma
Interventions
DRUG

Azacitidine Injection

Azacitidine Injection，SC and Dasatinib PO will be administered in T1 subtypes

DRUG

Dasatinib

Azacitidine Injection，SC and Dasatinib PO will be administered in T1 subtypes

DRUG

Linperlisib

Azacitidine Injection，SC and Linperlisib PO will be administered in T2 subtypes

DRUG

Tucidinostat

Tucidinostat PO and SHR2554 PO will be administered in T3.1 subtypes

DRUG

SHR2554

Tucidinostat PO and SHR2554 PO will be administered in T3.1 subtypes

DRUG

Camrelizumab

Camrelizumab and Apatinib will be administered in T3.2 subtypes

DRUG

Apatinib

Camrelizumab and Apatinib will be administered in T3.2 subtypes

Trial Locations (1)

200025

RECRUITING

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER